

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	ravulizumab
Brand Name	Ultomiris®
Dosage Forms	10 mg/mL and 100mg/mL concentrate for solution for intravenous infusion
Manufacturer	Alexion Pharma Canada Corp.
Submission Type	New Submission
Use Reviewed	Atypical hemolytic uremic syndrome to inhibit complement mediated thrombotic microangiopathy.
Canadian Agency for Drugs and Technologies in Health (CADTH) Reimbursement Reviews (CRR)	CRR recommended: to Reimburse with clinical criteria and/or conditions . Visit the CRR website for more details .
Provincial Review	The drug benefit council (DBC) now screens drug submissions under review by the CRR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. The DBC advised that because ravulizumab is similar to some of the other drugs used for the treatment of atypical hemolytic uremic syndrome, the Ministry base their decision on the CDEC decision and their own internal review.
Drug Coverage Decision	Non-benefit

Date	September 22, 2023
Reason(s)	The drug did not demonstrate significant advantages over eculizumab with respect to efficacy, safety and quality of life.

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Canadian Agency for Drugs and Technologies in Health \(CADTH\) Reimbursement Reviews\(CRR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.